Grifols (NASDAQ:GRFS) Trading Down 3.7% – What’s Next?

Grifols, S.A. (NASDAQ:GRFS)’s share price was down 3.7% on Friday . The stock traded as low as $7.16 and last traded at $7.20. Approximately 616,128 shares were traded during mid-day trading, a decline of 10% from the average daily volume of 683,670 shares. The stock had previously closed at $7.47.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Stock Performance

The firm has a 50-day simple moving average of $7.66 and a two-hundred day simple moving average of $8.19. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The company has a market capitalization of $5.05 billion, a price-to-earnings ratio of 6.13 and a beta of 0.41.

Institutional Trading of Grifols

Several large investors have recently added to or reduced their stakes in GRFS. R Squared Ltd acquired a new stake in shares of Grifols in the fourth quarter worth about $28,000. GAMMA Investing LLC grew its holdings in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 1,135 shares during the last quarter. Signaturefd LLC raised its position in shares of Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares during the period. Blue Trust Inc. lifted its stake in shares of Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock worth $52,000 after buying an additional 4,970 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Grifols during the 2nd quarter worth $89,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.